Interventions
toxicity, PD, death
DISEASE
Eligible patients were randomized 1:1 to receive pamiparib 60 mg orally (PO) twice a day (BID) or placebo 60 mg PO BID. Randomization was performed using an Interactive Response Technology system, took place ≤8 weeks after the last dose of first‐line platinum chemotherapy, and was stratified by region (China/Hong Kong/Taiwan vs. Australia/Europe/North America vs. Japan/South Korea vs. rest of world) and ECOG PS (0 vs. 1). There was no fixed duration of treatment in this study. Treatment with pamiparib or placebo continued until progressive disease (PD), unacceptable toxicity, death, or until another discontinuation criterion was met (including pregnancy, a major protocol deviation, withdrawal of consent, investigator's discretion, or start of a new anticancer therapy). A maximum of two dose reductions were permitted before the patient was permanently withdrawn from the study drug.